Neothetics, Inc. (NEOT)

[Ares_The_Investor]

I started the board on evfm

[Ares_The_Investor]

Let's move over the EVFM BOARD. This board is done.

[europtiger]

Yeah Looking better

[Striker77]

Starting to climb

[europtiger]

On my way Home.... will Start it

[snidely]

Good opportunity today. Most can’t trade so price may shoot up or down unevenly without proper balance

[snidely]

E*Trade is up

[Striker77]

Im mobile as well. What needs done to start it?

[europtiger]

Seems like Not everyone Anke to Trade yet

[europtiger]

Good thing our float now is just a Little more then one Million

[europtiger]

Can someone please Start the Board on New Ticker? I am just skiing and can't do it from the App

[europtiger]

Always needs a Little Time to settle when Ticker change

We know in 20 minutes

[Striker77]

Yeah, I dont get it but Fidelity showing 11.52 with 4.2% green. No value though, only showing my share amount.

[europtiger]

Bid down at 5$ wtf

[europtiger]

6:1 yesterday ah end should be 13,20

[europtiger]

Now it is on iHub

Bid 5,75

[europtiger]

Nasdaq homepage iHub noone Got the Ticker set yet

[europtiger]

Still NEOT with me

So i guess splitt was 1:6

And yes i do have shares,lots ;)

[Ares_The_Investor]

Etrade shows me the (EVFM) AT 11.51 AT this moment.So if you had neot your money and shares have already been switched over to EVFM. Even though you may have less shares at least your in a good company with serious growth potential. You will make money.

[europtiger]

IHub does Not Show the Ticker

[europtiger]

I belive there was a splitt

And i can't find the Ticker

[europtiger]

?!

[Ares_The_Investor]

EVFM new ticker at 11.51 right now!

[Ares_The_Investor]

Evofem Announces Closing Of Merger With Neothetics
Commences Trading on NASDAQ Capital Market on Thursday, January 18, 2018 Under Ticker Symbol "EVFM"


SAN DIEGO, Jan. 17, 2018 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), today announced the closing of the previously announced merger with Neothetics, Inc. (NASDAQ: NEOT). The merged company will operate as Evofem Biosciences, Inc. and will focus on the continued development and commercialization of women's healthcare products. The company will be led by the current Evofem management team under the leadership of Saundra Pelletier, Chief Executive Officer. The stock will trade on the Nasdaq Capital Market beginning on Thursday, January 18, 2018 under the ticker symbol "EVFM" and was assigned a new CUSIP number 30048L 104.

"The closing of this merger marks a significant milestone for Evofem, an achievement made possible only through the dedication and commitment of our management team and unwavering support of our investors," said Saundra Pelletier, CEO of Evofem Biosciences. "We are at a critical stage in our growth, making this a perfect time in our development as an organization to transition to the public markets, providing access to the resources necessary to move forward toward completion of our Phase 3 AMPOWER trial and prepare for the eventual commercialization of Amphora."

Immediately following the completion of the merger, an existing investor of Evofem, Invesco Asset Management Limited, as agent for and on behalf of its discretionary managed clients, purchased shares of common stock in the merged company for an aggregate purchase price of $20 million. The total cash balance available to the merged company upon closing of these transactions is approximately $18 million, net of transaction related fees and expenses.

As a result of the closing of the merger and the financing, the former Evofem stockholders own approximately 87 percent of the outstanding common stock of the merged company and the former Neothetics stockholders own approximately 13 percent of the outstanding common stock of the merged company. In addition, immediately prior to the merger on January 17, 2018, the company effected a 6:1 reverse stock split of shares of its common stock. Shares of the company's common stock will also begin trading on a post-split basis on the Nasdaq Capital Market beginning on Thursday, January 18, 2018. Following the completion of the merger, the $20 million financing and the reverse stock split, there were 17,757,165 issued and outstanding shares of the company's common stock.

"The completion of the merger and financing provide a strong foundation for Evofem's growth initiatives and the advancement of Amphora, a much-needed new offering in women's healthcare," said Thomas Lynch, Evofem Bioscience's Chairman. "We are now better positioned to capture this growing market opportunity and create value for patients and shareholders with a truly differentiated product."

The AMPOWER trial is a single-arm, Phase 3, open-label, multicenter, study in women aged 18-35 years of the contraceptive efficacy and safety of Amphora® contraceptive vaginal gel. The trial is expected to enroll approximately 1,350 women at risk of pregnancy at over 100 centers in the United States. The primary endpoint is the contraceptive efficacy of Amphora over seven cycles of use.

Amphora is an on-demand non-hormonal, woman controlled, surfactant-free investigational new drug being studied as a vaginal contraceptive and for the prevention of certain sexually transmitted infections. Amphora is also designated as a Qualified Infectious Disease Product (QIDP) by the U.S. Food & Drug Administration for two separate indications: the prevention of urogenital gonorrhea infection in women, and for the reduction of reoccurrence of bacterial vaginosis. These two QIDP designations are a significant advancement in Evofem Bioscience's efforts to make this drug available to women at risk of infection.

[Striker77]

Its probably only holders and insiders in the know still. Tomorrow should be real interesting.

[europtiger]

Very nice! Would have expected a Little More Action but it is the right direction;)

[Striker77]

2.20 and climbing in a/h....news is out

[Striker77]

BOOM time in a/h folks!!!

[snidely]

Merger approved!!!

[snidely]

Merger news today!!

[Ares_The_Investor]

Merger news tomorrow! $$$$$

[europtiger]

Thx for the Info

Lets see if we can move up here before friday,would b nice to see some higher prices before news

[Striker77]

No problem. Her name is Saundra Pelletier. There are a few speeches that come up on youtube. One is her at a podium at a womens convention and she explains the strategy behind a non profit merging with a public company for something that benefits the greater good like a contraceptive option for the world that is low cost and available to places without good medical resources. Makes total sense and can turn a world health need into a profitable business. The other speech is a Harvard grad speech, still interesting DD when researching who she is but the other one is the one that matters for us.

[gapole]

Thanks Striker for that info about CEO. Will try to watch on YT.

[snidely]

No apologies needed, didn’t take it like that at all. Lazy response on my part. I bought in the $8-10 and went down with first crash, bought more $1s and made cash and stupidly put it all in again around $2/3 figuring surely they got the formula right this time, crashed again but held! Averaged down a bit and sitting at $3 with some major cash on it. Only way to go is up with new company. Good pipeline, we’re lucky to get this merger.

[Striker77]

Typo.....56's.......I wish I had .36's. Dam cell phone keyboards.

[Striker77]

Hahaha, sorry if my tone was bossy sounding. Ive tried to do some background since I hold .36's. and I feel this is a good road we are on. After the drug failed it was a start from square 0 anyways, so Im glad to partner with Evofem and hearing what the real strategy is puts the future in perspective. Our new CEO is a Harvard Business grad and spoke at graduation two or three years back. She is very respected and has won a number of womens business awards as well. I was impressed and look forward to the merger.

[snidely]

Yessir.

[Striker77]

Vote yes. Best thing I can tell you is to watch the Evofem CEO speak. She is brilliant and in the end has the best trial of a modern instant contraceptive drug with alot of buzz. Neot had one primary drug in the pipe and it failed so I dont see why anyone would vote no. Neot had a bunch of cash but that was it and it was dwindling. This partnership will put us back in the game and Neot will be in the past since name will change. You will understand why a non profit is trying to buy a public corporation and the overall plan if you listen to the Evofem CEOs speeches on youtube. Its been her strategy for a bit now.

[snidely]

We don’t have an option or I would vote against split

[gapole]

i did that and hoping for good results.

[snidely]

It’s in the prospectus. Have to vote yes to all for the merger to go through.

[gapole]

I got a call last night from some rep for this Neot merger. As stated, they did not get enough response to proceed, so they were contacting shareholders directly.

Odd that I didn't receive anything from my broker..until early this am.
Anyway, in conversation, there are 7 issues to be addressed. One is they will do a reverse split. That does not excite me. He was talking 6 0r 10 for 1. Anyone have more info on that?

[snidely]

Yes sir. NEOT has let me down twice, third times a charm

[europtiger]

So Looks like one more week from today

[europtiger]

Ok Sweet thx for the Info!!

[snidely]

I finally got a call yesterday about the prospectus, they are actively calling shareholders to vote. Also they can extend again if needed. This merger is happening.

[europtiger]

Lets get that 2$ back today

[europtiger]

Got ya

[snidely]

Sorry I bought (dropped that much cash on it to buy more)